Carus Laboratories Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 23-10-2024
- Paid Up Capital ₹ 1.00 Cr
as on 23-10-2024
- Company Age 19 Year, 19 Days
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 3.00 M
as on 23-10-2024
- Revenue 21.26%
(FY 2023)
- Profit 3.09%
(FY 2023)
- Ebitda -1.88%
(FY 2023)
- Net Worth 29.15%
(FY 2023)
- Total Assets 26.99%
(FY 2023)
About Carus Laboratories
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 1.00 Cr.
The company has closed loans amounting to ₹3.00 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Krishna Devi, Jitender Pilani, and Arun Pilani serve as directors at the Company.
- CIN/LLPIN
U24231DL2005PTC144250
- Company No.
144250
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Dec 2005
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- LocationDelhi, Delhi
- Telephone
- Email Address
- Website
- Social Media
What products or services does Carus Laboratories Private Limited offer?
Carus Laboratories Private Limited offers a wide range of products and services, including Garden & Landscaping Products, Garden Trellis, Automobile Interiors & Accessories, Automotive Decals, Pain Killers, Forte Tablets, Animal Feed, Cattle Feed, Musical Equipment & Accessories, Percussion Instruments.
Who are the key members and board of directors at Carus Laboratories?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jitender Pilani  | Director | 30-Dec-2005 | Current |
| Krishna Devi | Director | 30-Dec-2005 | Current |
| Arun Pilani | Director | 05-Jul-2012 | Current |
Financial Performance of Carus Laboratories.
Carus Laboratories Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 21.26% increase. The company also saw a slight improvement in profitability, with a 3.09% increase in profit. The company's net worth Soared by an impressive increase of 29.15%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Carus Laboratories?
In 2023, Carus Laboratories had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Punjab National Bamk Creation Date: 11 Jun 2011 | ₹3.00 M | Satisfied |
How Many Employees Work at Carus Laboratories?
Carus Laboratories has a workforce of 579 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Carus Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Carus Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
